🎉 M&A multiples are live!
Check it out!

SanBio Valuation Multiples

Discover revenue and EBITDA valuation multiples for SanBio and similar public comparables like Cynata Therapeutics, Mesoblast, and Aroa Biosurgery.

SanBio Overview

About SanBio

SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.


Founded

2013

HQ

Japan
Employees

43

Website

sanbio.com

Financials

LTM Revenue $2.1M

LTM EBITDA -$22.6M

EV

$940M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

SanBio Financials

SanBio has a last 12-month revenue of $2.1M and a last 12-month EBITDA of -$22.6M.

In the most recent fiscal year, SanBio achieved revenue of n/a and an EBITDA of -$16.7M.

SanBio expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See SanBio valuation multiples based on analyst estimates

SanBio P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$29.1M -$30.9M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$31.1M -$36.9M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

SanBio Stock Performance

As of April 15, 2025, SanBio's stock price is JPY 2000 (or $13).

SanBio has current market cap of JPY 144B (or $957M), and EV of JPY 142B (or $940M).

See SanBio trading valuation data

SanBio Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$940M $957M XXX XXX XXX XXX $-0.27

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

SanBio Valuation Multiples

As of April 15, 2025, SanBio has market cap of $957M and EV of $940M.

SanBio's trades at 440.4x LTM EV/Revenue multiple, and -41.7x LTM EBITDA.

Analysts estimate SanBio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for SanBio and 10K+ public comps

SanBio Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $940M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -52.5x XXX XXX XXX
P/E -49.9x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -28.1x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get SanBio Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

SanBio Valuation Multiples

SanBio's NTM/LTM revenue growth is 372%

SanBio's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.7M for the same period.

Over next 12 months, SanBio's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate SanBio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for SanBio and other 10K+ public comps

SanBio Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 6% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $0.7M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

SanBio Public Comps

See public comps and valuation multiples for Regenerative Medicine comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Lineage Cell Therapeutics XXX XXX XXX XXX XXX XXX
Arovella Therapeutics XXX XXX XXX XXX XXX XXX
Aroa Biosurgery XXX XXX XXX XXX XXX XXX
Cynata Therapeutics XXX XXX XXX XXX XXX XXX
Mesoblast XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

SanBio M&A and Investment Activity

SanBio acquired  XXX companies to date.

Last acquisition by SanBio was  XXXXXXXX, XXXXX XXXXX XXXXXX . SanBio acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by SanBio

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About SanBio

When was SanBio founded? SanBio was founded in 2013.
Where is SanBio headquartered? SanBio is headquartered in Japan.
How many employees does SanBio have? As of today, SanBio has 43 employees.
Who is the CEO of SanBio? SanBio's CEO is Mr. Toru Kawanishi.
Is SanBio publicy listed? Yes, SanBio is a public company listed on TKS.
What is the stock symbol of SanBio? SanBio trades under 4592 ticker.
When did SanBio go public? SanBio went public in 2015.
Who are competitors of SanBio? Similar companies to SanBio include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics.
What is the current market cap of SanBio? SanBio's current market cap is $957M
What is the current revenue of SanBio? SanBio's last 12-month revenue is $2.1M.
What is the current EBITDA of SanBio? SanBio's last 12-month EBITDA is -$22.6M.
What is the current EV/Revenue multiple of SanBio? Current revenue multiple of SanBio is 440.4x.
What is the current EV/EBITDA multiple of SanBio? Current EBITDA multiple of SanBio is -41.7x.
Is SanBio profitable? Yes, SanBio is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.